What's in Eurofarma Laboratorios S.A.'s pipeline?

Eurofarma Laboratorios S.A. has 24 drugs in our index: 2 marketed, 0 filed, 22 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eurofarma Laboratorios S.A.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, AstraZeneca, Sanofi, Novartis, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eurofarma-laboratorios-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Eurofarma Laboratorios S.A. — Portfolio Competitive Intelligence Brief

Eurofarma Laboratorios S.A. pipeline: 2 marketed, 0 filed, 22 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 22 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cymbalta®	Cymbalta®	marketed
Nexium®	Nexium®	marketed	Proton pump inhibitor (PPI)	H+/K+-ATPase (proton pump)	Gastroenterology
N1087	N1087	phase 3
Higroton® Laboratório Novartis	Higroton® Laboratório Novartis	phase 3	Thiazide-like diuretic	Sodium-chloride cotransporter (NCC)	Cardiovascular
Formoterol/Fluticasone	Formoterol/Fluticasone	phase 3	Long-acting beta-2 agonist / Inhaled corticosteroid combination	Beta-2 adrenergic receptor; Glucocorticoid receptor	Respiratory / Pulmonology
Foraseq®	Foraseq®	phase 3	ICS/LABA combination	Glucocorticoid receptor; Beta-2 adrenergic receptor	Respiratory/Pulmonology
Comparator - Trimbow®	Comparator - Trimbow®	phase 3	Triple combination inhaler (ICS/LABA/LAMA)	Beta-2 adrenergic receptor, glucocorticoid receptor, muscarinic M3 receptor	Respiratory / Pulmonology
Cosamin DS® (Nutramax)	Cosamin DS® (Nutramax)	phase 3	Dietary supplement / nutraceutical		Rheumatology / Orthopedics
Placebo of the experimental drug	Placebo of the experimental drug	phase 3
Noex	Noex	phase 3	Selective serotonin reuptake inhibitor	Serotonin transporter	Psychiatry
Budecort Aqua	Budecort Aqua	phase 3	Inhaled corticosteroid (ICS)	Glucocorticoid receptor (GR)	Respiratory / Pulmonology
Lactase Oral Tablets	Lactase Oral Tablets	phase 3	Enzyme replacement therapy	Lactose (substrate); lactase enzyme (β-galactosidase)	Gastroenterology

Therapeutic area mix

Other · 5
Diabetes · 4
Respiratory / Pulmonology · 3
Gastroenterology · 2
Respiratory/Pulmonology · 1
Rheumatology / Orthopedics · 1
Cardiovascular · 1
Urology · 1
Dermatology · 1
Oncology, Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 5 shared drug classes
AstraZeneca · 4 shared drug classes
Sanofi · 4 shared drug classes
Novartis · 3 shared drug classes
Takeda · 3 shared drug classes
Abbott · 2 shared drug classes
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
Allergan · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Eurofarma Laboratorios S.A.:

Cite this brief

Drug Landscape (2026). Eurofarma Laboratorios S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eurofarma-laboratorios-s-a. Accessed 2026-05-16.